Your browser doesn't support javascript.
loading
Mathematical modeling of the evolution of resistance and aggressiveness of high-grade serous ovarian cancer from patient CA-125 time series.
Jitmana, Kanyarat; Griffiths, Jason I; Fereday, Sian; DeFazio, Anna; Bowtell, David; Adler, Frederick R.
Afiliação
  • Jitmana K; Department of Mathematics, The University of Utah, Salt Lake City, Utah, The United States of America.
  • Griffiths JI; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, The United States of America.
  • Fereday S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • DeFazio A; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Bowtell D; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Adler FR; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
PLoS Comput Biol ; 20(5): e1012073, 2024 May.
Article em En | MEDLINE | ID: mdl-38809938
ABSTRACT
A time-series analysis of serum Cancer Antigen 125 (CA-125) levels was performed in 791 patients with high-grade serous ovarian cancer (HGSOC) from the Australian Ovarian Cancer Study to evaluate the development of chemoresistance and response to therapy. To investigate chemoresistance and better predict the treatment effectiveness, we examined two traits resistance (defined as the rate of CA-125 change when patients were treated with therapy) and aggressiveness (defined as the rate of CA-125 change when patients were not treated). We found that as the number of treatment lines increases, the data-based resistance increases (a decreased rate of CA-125 decay). We use mathematical models of two distinct cancer cell types, treatment-sensitive cells and treatment-resistant cells, to estimate the values and evolution of the two traits in individual patients. By fitting to individual patient HGSOC data, our models successfully capture the dynamics of the CA-125 level. The parameters estimated from the mathematical models show that patients with inferred low growth rates of treatment-sensitive cells and treatment-resistant cells (low model-estimated aggressiveness) and a high death rate of treatment-resistant cells (low model-estimated resistance) have longer survival time after completing their second-line of therapy. These findings show that mathematical models can characterize the degree of resistance and aggressiveness in individual patients, which improves our understanding of chemoresistance development and could predict treatment effectiveness in HGSOC patients.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antígeno Ca-125 / Resistencia a Medicamentos Antineoplásicos Limite: Female / Humans Idioma: En Revista: PLoS Comput Biol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antígeno Ca-125 / Resistencia a Medicamentos Antineoplásicos Limite: Female / Humans Idioma: En Revista: PLoS Comput Biol Ano de publicação: 2024 Tipo de documento: Article